113 related articles for article (PubMed ID: 11259122)
1. Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra.
Galvin JE; Schuck TM; Lee VM; Trojanowski JQ
Exp Neurol; 2001 Apr; 168(2):347-55. PubMed ID: 11259122
[TBL] [Abstract][Full Text] [Related]
2. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra.
Mori F; Nishie M; Kakita A; Yoshimoto M; Takahashi H; Wakabayashi K
J Neuropathol Exp Neurol; 2006 Aug; 65(8):808-15. PubMed ID: 16896314
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
4. Synucleins and their relationship to Parkinson's disease.
von Bohlen Und Halbach O
Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
[TBL] [Abstract][Full Text] [Related]
5. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
6. The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases.
Duda JE; Shah U; Arnold SE; Lee VM; Trojanowski JQ
Exp Neurol; 1999 Dec; 160(2):515-22. PubMed ID: 10619569
[TBL] [Abstract][Full Text] [Related]
7. The nigro-striatal and nigro-amygdaloid pathways undergo different degeneration processes in brains of dementia with Lewy bodies.
Iseki E; Marui W; Yamamoto R; Togo T; Katsuse O; Kato M; Iwatsubo T; Kosaka K; Arai H
Neurosci Lett; 2005 May 20-27; 380(1-2):161-5. PubMed ID: 15854770
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
9. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein.
Galvin JE; Uryu K; Lee VM; Trojanowski JQ
Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13450-5. PubMed ID: 10557341
[TBL] [Abstract][Full Text] [Related]
10. NACP/alpha-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC).
Yokota O; Terada S; Ishizu H; Tsuchiya K; Kitamura Y; Ikeda K; Uéda K; Kuroda S
Acta Neuropathol; 2002 Oct; 104(4):333-41. PubMed ID: 12200618
[TBL] [Abstract][Full Text] [Related]
11. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
12. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.
Song DD; Shults CW; Sisk A; Rockenstein E; Masliah E
Exp Neurol; 2004 Apr; 186(2):158-72. PubMed ID: 15026254
[TBL] [Abstract][Full Text] [Related]
13. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.
Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL
J Neurochem; 2004 Jun; 89(5):1126-36. PubMed ID: 15147505
[TBL] [Abstract][Full Text] [Related]
14. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Galvin JE
Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
[TBL] [Abstract][Full Text] [Related]
15. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
[TBL] [Abstract][Full Text] [Related]
17. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
Park JY; Lansbury PT
Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
[TBL] [Abstract][Full Text] [Related]
18. Neuronal and glial accumulation of alpha- and beta-synucleins in human lipidoses.
Suzuki K; Iseki E; Togo T; Yamaguchi A; Katsuse O; Katsuyama K; Kanzaki S; Shiozaki K; Kawanishi C; Yamashita S; Tanaka Y; Yamanaka S; Hirayasu Y
Acta Neuropathol; 2007 Nov; 114(5):481-9. PubMed ID: 17653558
[TBL] [Abstract][Full Text] [Related]
19. BDNF is induced by wild-type alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line.
Kohno R; Sawada H; Kawamoto Y; Uemura K; Shibasaki H; Shimohama S
Biochem Biophys Res Commun; 2004 May; 318(1):113-8. PubMed ID: 15110760
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
